Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives
3 Manish Mattoo (CEO), Ravi Gothwal (Head, Investor Relations), Sanjeev Kumar (CFO)
Analysts
7 Aditya Chheda, Aryan Jain, Chinmay, Devang Patel, Himanshu Binani, Jyothish Vijayan, Rajat, Sumit Gupta, Vedant Nilekar
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹6,951 million | ~13% YoY growth; 16 of 25 centers (excl. North Bangalore) hit record quarterly revenues; North Bangalore contributed ₹67 million in first quarter |
| Patient Volumes | +11% YoY | Primary growth driver; broad-based across clusters |
| ARPP | +2% YoY | Driven by annual price hike and favorable payer mix; partly offset by change in case mix and lower high-value, low-margin therapies |
| Adjusted EBITDA | ₹1,339 million | +20% YoY; excl. North Bangalore losses and one-off costs; reported EBITDA ₹1,223 million |
| Adjusted EBITDA Margin | 19.4% | +120 bps YoY from 18.2%; driven by payer mix improvement and operating leverage |
| Non-Institutional Revenue Mix | 69% | Up from 67% YoY; +17% YoY growth in non-institutional business |
| Institutional Revenue (West) | -16% YoY | Deliberate decline in low-margin scheme business, particularly Gujarat; margin accretive |
| North Bangalore Revenue | ₹67 million | First quarter of operations; 550+ new patient registrations, 300+ admissions |
| Drug Price Capping Impact | ~1.5% of top line | Discontinued low-margin chemo drugs; margin accretive on like-to-like basis |
| Capex (Q1 FY27) | ₹750 million | ₹350 million growth capex, ₹400 million maintenance capex |
| Operating Cash Flow | ~₹70 crores | ₹125 crores before working capital changes |
| Marketing Spend | 2.9% of sales | Up 20%+ YoY; targeted 2.5%-2.6% range over medium term |
Geographic & Segment Commentary
- South Cluster: Revenue grew ~16% YoY, supported by healthy patient volumes and realizations. Includes North Bangalore hospital contribution of ₹67 million. Continued improvement in cash and TPA mix across Bangalore COE and Vizag cluster.
- West Cluster: Revenue grew 9% YoY on 11% volume growth; Maharashtra grew 14%+, Gujarat remained moderate. Institutional business declined >16% YoY, consistent with strategic focus on improving quality of revenues. ARPP broadly stable; case mix shift towards medical oncology patients with drugs.
- East Cluster: Delivered strong 22% YoY revenue growth, driven by robust volume growth. ARPP temporarily moderated, but significant increase in patient throughput provides foundation for future growth.
- Revenue Buckets: Hospitals with >₹10 crore/month revenue increased from 4 to 7; ₹5-10 crore bucket reduced from 14 to 11; <₹5 crore bucket increased from 6 to 7 with North Bangalore addition.
Company-Specific & Strategic Commentary
- Fertility Business Divestment: Completed divestment of Milann fertility business at end of June 2026, sharpening strategic focus on core oncology platform.
- Balance Sheet Strengthening: Successful rights issue completed; utilized funds for debt repayment (₹170 crores), increased Whitefield facility stake from 51% to 85% (₹120 crores), expenses (₹50 crores), and general corporate purposes (₹95 crores).
- North Bangalore Commissioning: Hospital commenced operations May 2026; commissioned South India's second MR LINAC in July 2026; clinician onboarding complete; expects monthly breakeven within FY27 and optimal utilization (60-65%) in 3-4 years.
- Capacity Expansion: Added 121 operational beds in Q1; plans for 65 beds in FY27, 520 beds in FY28-29, 230 beds in FY30; ~60% of expansion through brownfield projects; three greenfield projects in pipeline (Whitefield, Maharashtra, and one more).
- Clinical Capabilities: Commissioned new LINAC in Rajkot; added two surgical robotic systems (Nashik and Bangalore COE); advanced complex oncology cases including CAR-T cell therapies, rare anatomical surgeries, and minimally invasive thoracic procedures. Onboarded ~20 oncologists in last 4-5 months.
- New CFO: Sanjeev Kumar joined as CFO bringing three decades of experience across finance, strategy, and business transformation.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | Mid-teens | Management confident of delivering mid-teen growth from existing centers plus new greenfield and brownfield expansions; unchanged outlook |
| EBITDA Margin (2 years) | 21%-22% | Driven by payer mix improvement, case mix enhancement, operating leverage from maturing centers |
| EBITDA Margin (4-5 years) | 24%-25% | Long-term aspiration supported by clinical differentiation, precision oncology investments, and North Bangalore ramp-up |
| North Bangalore Losses | Peak EBITDA loss in Q1 FY27 | Losses to reduce reasonably in next few quarters; monthly breakeven expected within FY27 |
| Bed Additions | 65 (FY27), 520 (FY28-29), 230 (FY30) | ~60% brownfield; greenfield projects in Whitefield (end FY27/FY28) and Maharashtra (subsequent year) |
| Drug Price Capping Impact | ~1.5% of top line | Impact to remain in similar vicinity for next few quarters, might marginally decline as replaced by higher-margin therapies |
| Maintenance Capex | ~₹100 crores per annum | Consistent annual target |
| Marketing Spend | 2.5%-2.6% of sales | Medium-term target, currently at 2.9% due to North Bangalore launch |
Risks & Constraints
| Risk | Context |
|---|---|
| Drug Price Capping (CGHS) | Government price revision on certain chemo drugs resulted in 1.5% top-line impact in Q1. Discontinued drugs were high-value but low-margin, making impact margin accretive. Management expects similar impact for next few quarters, gradually reducing as replaced by higher-margin therapies. |
| North Bangalore Ramp-Up | New hospital in early operational stage; 550 registrations and 300 admissions in first quarter. Peak EBITDA loss reached in Q1; monthly breakeven expected within FY27, but full optimal utilization (60-65%) only expected in 3-4 years. Insurance empanelments and brand awareness building remain key execution risks. |
| Institutional Revenue Decline | West cluster institutional business declined >16% YoY, moderating cluster growth. Deliberate strategy to cut low-margin scheme business; management expects progressive replacement with high-value cash/non-institutional patients. Risk of growth moderation during transition period. |
| Greenfield Execution | Two greenfield projects (Whitefield, Maharashtra) totaling 180 beds in FY28-29 pipeline; execution delays could impact growth trajectory. Details shared once finalized; typical construction and regulatory approval risks apply. |
| ESOP Charge Impact | New ESOP scheme approval in final stages; charge expected to hit P&L in Q2 FY27. Quantum not yet disclosed, could impact near-term profitability. |
| Utilization Headroom | Existing facilities can manage up to 75-80% utilization; South cluster at 68% in FY26. While headroom exists, inability to drive occupancy improvement could pressure returns on expanded capacity. |
Q&A Highlights
Revenue Bucket Migration
- Question: How did performance across revenue buckets (₹10 crore+, ₹5-10 crore, <₹5 crore per month) trend this quarter? (Sumit Gupta, Antique)
- Answer: Hospitals >₹10 crore/month increased from 4 to 7; ₹5-10 crore bucket decreased from 14 to 11; <₹5 crore bucket increased from 6 to 7 with North Bangalore added. Growth broad-based across hospital sizes. (Manish Mattoo)
Greenfield Timeline and Debt Reduction
- Question: What is the strategy for reducing financial costs and borrowings? (Chinmay, Individual Investor)
- Answer: Rights issue proceeds used for debt repayment of ₹170 crores. Will continue to fund growth through mix of debt and internal accruals; expect interest cost moderated this year versus last year. (Sanjeev Kumar)
Greenfield Commissioning Timeline
- Question: When will greenfield projects be commissioned? (Sumit Gupta, Antique)
- Answer: 180 greenfield beds from two projects: Whitefield (South) expected at end of FY27/FY28; Maharashtra (West) in subsequent year. (Manish Mattoo)
Revenue Growth Drivers and Margin Outlook
- Question: With 8% bed CAGR, how will mid-teen revenue growth be achieved? What about EBITDA losses from North Bangalore and ESOP impact? (Aditya Chheda, InCred)
- Answer: Confident of mid-teen growth from existing centers plus expansions. North Bangalore losses peaked in Q1; expected to reduce reasonably over coming quarters with clinician ramp-up and insurance empanelments. ESOP charge to hit P&L in Q2. (Manish Mattoo); drug discontinuation impacted top line ~1.5% but margin accretive. (Manish Mattoo)
Operational Excellence Initiatives
- Question: What specific initiatives are underway for cost optimization? (Jyothish Vijayan, Moat Financial Services)
- Answer: Opportunities across all cost line items including manpower and fixed costs; using automation and data analytics. Dedicated team for patient experience improvement; focusing on clinical productivity through technology support and non-clinical productivity through conversion improvement and revenue leakage plugging. (Manish Mattoo)
Brownfield Bed Details
- Question: The 340 brownfield beds in FY28-29 don't add up from slide 12; what are the extra beds? (Himanshu Binani, Anand Rathi)
- Answer: Expansion across all 25 centers; besides major additions, smaller hospitals (Baroda, Cuttack, Ranchi) will add 10-15 beds each. Locations assessed annually based on capacity and utilization. (Ravi Gothwal, Sanjeev Kumar)
Capex Details
- Question: How much capex spent in Q1, and what is annual maintenance capex? (Devang Patel, Sameeksha Capital)
- Answer: Q1 capex ~₹750 million - ₹350 million growth, ₹400 million maintenance. Maintenance capex ~₹100 crores per annum target. (Sanjeev Kumar)
Cluster Utilization
- Question: What are utilization levels across clusters? (Sumit Gupta, Antique)
- Answer: Utilization only disclosed annually at financial year end. Occupancy improved sequentially; 11% volume growth indicates better asset utilization. (Sanjeev Kumar)
Milann Exit Strategy
- Question: What triggered the exit from Milann fertility business? (Jyothish Vijayan, Moat Financial Services)
- Answer: Focus on building core oncology - CAR-T cell therapies, bone marrow transplants, robotic surgery, precision diagnostics, advanced radiation technologies. Investment aims to give clinicians tools for more complex procedures and better outcomes. (Manish Mattoo)
Marketing Spend
- Question: Current marketing spend percentage and target? (Jyothish Vijayan, Moat Financial Services)
- Answer: Marketing at 2.9% of sales, up 20% YoY due to North Bangalore launch. Will keep around 2.5%-2.6% range given specialty nature and competitive intensity. (Manish Mattoo)
Long-Term Margin Levers
- Question: What are the levers for reaching 24-25% EBITDA margins? (Vedant Nilekar, ICICI Securities)
- Answer: Biggest lever is payer mix improvement - changed by 200 bps positively in Q1. Investing in clinical technology (tomotherapy, MR LINAC, surgical robots) and talent (20 oncologists onboarded in 4-5 months) to improve case mix. Operating leverage from maturing centers; North Bangalore loss reduction as additional lever. (Manish Mattoo)
Mission Performance Assessment and Margin Potential
- Question: Has progress been in line with expectations on top-line and margin expansion? Can HCG reach 23-25% margins in 2-3 years? (Rajat, Tata Mutual Fund)
- Answer: Could have done better on top line due to price capping headwinds, but margin trajectory good. Confident of reaching 24-25% EBITDA margins in next few years given levers in place, presence across markets, maturing centers, clinical differentiation, and patient trust. (Manish Mattoo)
Operating Cash Flow
- Question: What was cash generation during the quarter? (Rajat, Tata Mutual Fund)
- Answer: Operating cash flow before working capital changes ~₹125 crores; net cash flow from operating activities ~₹70 crores. (Manish Mattoo)
Government Business and Case Mix
- Question: How much revenue from government business attributed to CGHS; what was price revision impact? Steps to improve case mix? (Aryan Jain, Individual Investor)
- Answer: Price capping impact ~1.5% on top line with positive margin impact; detailed quantification available offline. Case mix improvement driven by technology infusion (MR LINAC, tomotherapy, surgical robots), CAR-T cell therapy programs, bone marrow transplant programs, theranostics, precision diagnostics, and new clinician recruitment with specialized skills. (Manish Mattoo)
Key Takeaway
Healthcare Global Enterprises delivered a strong Q1 FY27 with revenue of ₹6,951 million (+13% YoY) and Adjusted EBITDA margin expansion to 19.4% (+120 bps YoY), despite a 1.5% top-line headwind from CGHS drug price capping. Growth was broad-based across clusters, with 16 of 25 centers achieving record quarterly revenues, driven by 11% volume growth and 2% ARPP improvement. The company completed its strategic exit from the fertility business and utilized rights issue proceeds for debt reduction (₹170 crores) and increased Whitefield stake to 85%, strengthening its balance sheet for the expansion pipeline. Management remains confident of mid-teen revenue growth and targets 21-22% EBITDA margins within two years and 24-25% over four to five years, driven by payer mix improvement, clinical complexity enhancement, and North Bangalore ramp-up (monthly breakeven expected in FY27). With 121 beds added in the quarter and 815 beds planned through FY30 (~60% brownfield), execution of the capacity pipeline and insurance empanelments at new facilities remain the key watch points alongside the evolving government pricing environment.